
Guglielmo Di Molfetta
Articles
-
2 weeks ago |
alz-journals.onlinelibrary.wiley.com | Nicholas Ashton |Andrea L. Benedet |Guglielmo Di Molfetta |Ilaria Pola
1 BACKGROUND Discovery plasma proteomics has long since demonstrated a differential signal in the blood of patients clinically diagnosed with Alzheimer's disease (AD).1, 2 These earlier studies used agnostic methods to discover novel biomarkers—proteomic technologies not predicated on any a priori hypotheses in a case-control approach1, 3-6 but later evolved to an endophenotype design based on pathology; brain atrophy measures,1, 7-9 cerebrospinal fluid (CSF) biomarkers,10 or amyloid beta...
-
Jul 29, 2024 |
medrxiv.org | Nicholas Ashton |Andrea L. Benedet |Ilaria Pola |Guglielmo Di Molfetta
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon,...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →